Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909Â and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909Â and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Nine Mile Metals Announces Completion of DDH WD-26-03, and Confirms Continued Mineralization at the Wedge Deposit
Standard Uranium Confirms Uranium Enrichment in All Winter 2026 Drill Holes at the Corvo Uranium Project
Nevada Sunrise Completes Soil Survey Program at the Fivemile Gold Project, Cortez Mining District, Nevada
